AddToAny

Alzheimer's in the wind

Alzheimer's disease (AD) has puzzled scientists for over a century. Years and years of work on AD has yet to produce a cure, and failing drug candidates have proven to be common. AD is the most common form of dementia and deprives affected individuals of a full life. In the end, individuals, families, and societies suffer from this burden. Here, we present a new piece for the AD puzzle.
Human lifespan is currently increasing. With new cases of AD increasing in parallel, large socio-economic challenges are becoming apparent and science has yet to produce a cure. Many attempts have been made to produce novel drugs to intervene with or reverse disease progression, but many have also failed during clinical trials. This problem is complicated by the lack of natural model organisms: natural analogues of the disease-causing proteins are hard to find.
The three common accepted pillars of AD aetiologies are neuroinflammation,amyloid (A) plaques and tau tangles; all these symptoms serve as potential targets for drug development. As A plaques seemed directly related to the severity of disease, it was thought that removal of A plaques could have therapeutic potential and so were targeted. Unfortunately, antibodies directed against these plaques disappointed in clinical trials, making them one of the many examples of how AD continues to hide its exact etiology. If these plaques are not the only problem, what else is there? Newer research has shown that defects in a process called mitophagy could be a new hallmark of the disease. A research group at UiO and Akershus University Hospital lead by Dr. Evandro
Gå til mediet

Flere saker fra NBS-nytt

Forord
NBS-nytt 14.02.2021
Det første NBS kontaktmøtet fant sted i 1964, og ideen var hvert år å samle det biokjemiske miljøet i Norge i en atmosfære som ikke bare inkluderte det faglige, men også det sosiale!
NBS-nytt 14.02.2021
Abstract:
NBS-nytt 14.02.2021
Det norske bioteknologiselskapet Vaccibody går så det griner. Hva driver de med?
NBS-nytt 14.02.2021
Som eldre lesere av NBS-nytt vil vite, har en av Biorabiatens viktigste samfunnsoppgaver i en årrekke vært å fungere som et korrektiv til Norges forskningsråd.
NBS-nytt 14.02.2021

Nyhetsbrev

Lag ditt eget nyhetsbrev:

magazines-image

Mer om mediene i Fagpressen

advokatbladet agenda-316 allergi-i-praksis appell arbeidsmanden arkitektnytt arkitektur-n astmaallergi automatisering baker-og-konditor barnehageno batmagasinet bedre-skole bioingenioren bistandsaktuelt blikkenslageren bobilverden bok-og-bibliotek bondebladet buskap byggfakta dagligvarehandelen demens-alderspsykiatri den-norske-tannlegeforenings-tidende diabetes diabetesforum din-horsel energiteknikk fagbladet farmasiliv finansfokus fjell-og-vidde fontene fontene-forskning forskerforum forskningno forskningsetikk forste-steg fotterapeuten fri-tanke frifagbevegelse fysioterapeuten gravplassen handikapnytt helsefagarbeideren hk-nytt hold-pusten HRRnett hus-bolig i-skolen jakt-fiske journalisten juristkontakt khrono kilden-kjonnsforskningno kjokkenskriveren kjottbransjen kommunal-rapport Kontekst lo-aktuelt lo-finans lo-ingenior magasinet-for-fagorganiserte magma medier24 museumsnytt natur-miljo nbs-nytt nettverk nff-magasinet njf-magasinet nnn-arbeideren norsk-landbruk norsk-skogbruk ntl-magasinet optikeren parat parat-stat politiforum posthornet psykisk-helse religionerno ren-mat samferdsel seilmagasinet seniorpolitikkno sikkerhet skog skolelederen sykepleien synkron tannhelsesekreteren Tidsskrift for Norsk psykologforening traktor transit-magasin transportarbeideren uniforum universitetsavisa utdanning vare-veger vvs-aktuelt